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ABSTRACT
SGLT2 (for “Sodium GLucose coTransporter” 
protein 2) is the major protein responsible 
for glucose reabsorption in the kidney and its 
inhibition has been the focus of drug discovery 
efforts to treat type 2 diabetes. In order to 
better clarify the human tissue distribution of 
expression of SGLT2 and related members of 
this cotransporter class, we performed TaqMan™ 
(Applied Biosystems, Foster City, CA, USA) 
quantitative polymerase chain reaction (PCR) 
analysis of SGLT2 and other sodium/glucose 
transporter genes on RNAs from 72 normal tissues 
from three different individuals. We consistently 
observe that SGLT2 is highly kidney specific 
while SGLT5 is highly kidney abundant; SGLT1, 
sodium-dependent amino acid transporter 
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(SAAT1), and SGLT4 are highly abundant in small 
intestine and skeletal muscle; SGLT6 is expressed 
in the central nervous system; and sodium myo-
inositol cotransporter is ubiquitously expressed 
across all human tissues.
Keywords: quantitative PCR; SGLT2; sodium-
glucose cotransporter protein; tissue expression; 
type 2 diabetes
INTRODUCTION
As a worldwide medical and economic 
problem type 2 diabetes is expanding inter-
nationally. The International Diabetes 
Federation estimates that in 2010 approxim-
ately 285 million individuals have type 2 
diabetes across the world;1 this number is 
expected to expand to 439 million individuals 
by 2030. Diabetes imposes a significant health 
and economic burden, and factoring in the 
additional costs of undiagnosed diabetes, 
prediabetes, and gestational diabetes, the total 
cost of diabetes in the US in 2007 amounted 
to $218 billion.2 Despite the availability of 
several oral and injectable therapies for type 2 
diabetes, there remains significant unmet 
medical need in this disease, justifying the 58 Diabetes Ther (2010)  1(2):57-92.
search for more efficacious and safe treatments 
that can prevent disease progression and protect 
patients from microvascular and macrovascular 
complications. Among the types of therapies 
under development, inhibitors of SGLT2 (for 
“Sodium GLucose coTransporter” protein 2) 
represent a promising new class.3,4
One consideration for choosing a molecular 
target for the identification of a new treatment 
of a chronic disease such as type 2 diabetes is 
the spectrum of tissues in which the target of 
interest is expressed. A molecular target with 
a ubiquitous pattern of expression could pose 
concerns related to the activities of agonists or 
antagonists to this target in a wide variety of 
tissues, whereas a molecular target expressed in 
a restricted number of tissues might suggest a 
more selective pharmacologic profile. We have 
evaluated the expression pattern of SGLT2 
and related family members by quantitative 
reverse transcription real-time polymerase 
chain reaction (RT-PCR) methodology in order 
to better understand the potential impact of a 
selective SGLT2 inhibitor in vivo.
Table 1. SGLT (sodium glucose cotransporter protein) family members. 1A and 1B: The common names, system names, and 
human reference sequence numbers of the 12 SGLT family members are listed. The putative substrates of the transporters 
and the chromosomal locations of the transporter genes are given in the tables. 1C: Percentage of protein sequence identity 
among SGLT family members as determined with VectorNTI AlignX software.Diabetes Ther (2010)  1(2):57-92. 59
There are more than 200 SGLT family 
members, including 12 human orthologs.5 Based 
on sequence homology, these 12 SGLT family 
members can be divided into two subfamilies, 
as shown in Table 1. SGLT1, SGLT2, sodium-
dependent amino acid transporter (SAAT1; 
also known as SGLT3), sodium myo-inositol 
cotransporter (SMIT), SGLT4, SGLT5, and SGLT6 
belong to one subfamily, sharing between 45% 
and 70% protein sequence identity amongst 
themselves. Most of the members of this 
subfamily transport or bind sugar molecules. 
The five other solute carrier family 5A (SLC5A) 
family members Na+/I- symporter (NIS), 
sodium-dependent multivitamin transporter 
(SMVT), choline transporter (CHT), apical 
iodide transporter/sodium monocarboxylate 
cotransporter 1 (AIT/SMCT1), and SMCT2 form 
another subfamily. They share between 40% 
and 50% protein sequence identity amongst 
themselves; members of this latter subfamily 
are involved in the cotransport of sodium with 
other physiologically important molecules 
such as iodide, ascorbate, biotin, pantothenate, 
lipoate, choline, and monocarboxylates such as 
lactate.5 Since only 18% to 20% protein sequence 
identity exists between the two subfamilies, the 
focus of our studies was the sugar-binding class 
of SGLT cotransporters most closely related to 
SGLT2 (Table 1).
The first sugar-binding SGLT sequence to be 
cloned, by Wright and colleagues, was the high-
affinity sodium-glucose cotransporter SGLT1, 
which was found to be expressed in the small 
intestinal mucosa6 and associated with glucose 
and galactose transport at that site. SGLT1 was 
later found to be expressed in many tissues 
across the body,7 and mutations in SGLT1 were 
associated with the human genetic syndrome 
glucose-galactose malabsorption.8 SGLT2 was 
cloned subsequently, and was characterized 
as a low-affinity sodium-glucose cotransporter 
expressed in the renal early proximal tubule.9,10
SAAT1 was first cloned as a sodium-amino 
acid cotransporter11 but was later found to 
have glucose cotransporter activity.12 It was 
found in kidney, small intestine, and other 
tissues and is now suggested to be a sodium-
dependent glucose sensor rather than a 
sodium-glucose cotransporter.13 SMIT is an 
osmoregulatory sodium-inositol cotransporter 
found in many tissues including brain and 
cardiac myocytes.14,15 SGLT4 is a low-affinity 
sodium-dependent transporter for mannose 
and fructose found in kidney and small 
intestine tissue.16 SGLT5 was identified in the 
Mammalian Gene Collection (MGC) human 
cDNA sequencing project, by similarity to other 
SGLT family members.17 SGLT6 (also known 
as KST1 or SMIT2) was identified as a novel 
sodium-glucose cotransporter18 located within 
a genomic region associated with infantile 
convulsion and choreoathetosis as well as 
benign familial infantile convulsion diseases. 
It was found to be able to transport myo-
inositol in a sodium-dependent manner.19 Even 
though the functional activities of these SGLT 
family members have been described, there has 
not been a systematic study of the expression 
profiles of this family across the same broad set 
of normal human tissues.
There have been conflicting reports about the 
mRNA expression profile of SGLT2 in human 
tissues. It was initially reported to be expressed 
predominantly in the kidney using northern blot 
techniques;9,20 however, Wright and colleagues 
have subsequently reported a broader pattern of 
tissue expression of SGLT2 beyond the kidney 
using RNase protection methods, although 
no detailed methods or data were presented.21
In 2003, Zhou et al.22 employed quantitative 
RT-PCR techniques to show that SGLT2 was 
ubiquitously expressed in most human tissues. 
In 2005, however, Tazawa et al.16 used the 60 Diabetes Ther (2010)  1(2):57-92.
same methodological approach but reported 
contradictory findings: SGLT2 was primarily 
expressed in the kidney and to a smaller degree 
in the small intestine. It has also been reported 
that in mice, SGLT2 is specifically expressed 
in kidney proximal tubule.23 Because SGLT2 
inhibitor compounds are being developed by 
several pharmaceutical companies as antidiabetic 
agents which inhibit renal glucose reabsorption, 
it has become increasingly important to verify 
the tissue expression profile of SGLT2. To our 
knowledge, no antibodies shown to be specific 
for individual human SGLT family members 
have been developed successfully to enable 
expression profiling based on the protein level, 
although antibodies to one or more members 
of the protein family have been reported.6,24-29 
Therefore, we chose to verify the expression 
profile of seven SGLT family members in human 
tissues by quantitative PCR methods across a 
broad panel of human tissues.
MATERIALS AND METHODS
Reverse Transcription-Coupled Quantitative 
Real-Time PCR
AmpliTaq Gold™ DNA Polymerase and 
AmpErase® Uracil-N-Glycosylase were obtained 
from Applied Biosystems (Warrington, UK) and 
MMLV reverse transcriptase was purchased 
from Promega (Southampton, UK). TRIzol® and 
DNase I were obtained from Invitrogen (Paisley, 
UK). TaqMan™ probes and oligonucleotide 
primers were purchased from Sigma-Genosys 
(Haverhill, UK) and deoxynucleotide 
triphosphates were obtained from BioGene 
Limited (Kimbolton, UK). Purification of total 
RNA and quantitative RT-PCR was performed 
as previously described.30 Briefly, total RNA 
was extracted from snap-frozen human tissues 
using TRIzol® according to the manufacturer’s 
instructions. Purified RNA samples were subject 
to a number of quality control criteria before 
being passed as suitable for quantitative 
RT-PCR.30 RNA samples were treated with 
DNase I to remove any residual genomic DNA 
and were reverse transcribed using gene-specific 
primers.
Quantitative RT-PCR was performed with 
TaqMan primer/probe sets designed using 
PrimerExpress software (Applied Biosystems). 
To analyze the expression of the SGLT2 locus we 
used five primer/probe combinations: four new 
designs and one previously published.22 These 
primer/probe sets were designed to survey the 
entire locus and to be specific with respect to 
other known expressed sequences, as well as 
specific for spliced transcripts versus nonspliced 
transcripts and genomic DNA. The primer/probe 
combinations were not matched for amplification 
efficiency, hence the absolute transcript number 
detected with each primer/probe set can be 
expected to vary. The sequences of the primer/
probe sets utilized in these studies are available 
in the Appendix, Additional Table S1.
The amplification reaction was performed 
using AmpliTaq GoldTM polymerase in a 
standard PCR buffer containing cDNA prepared 
from 100 ng of total RNA. Uracil N-glycosylase 
was included in all reactions to prevent cross-
contamination and amplification of previous 
PCR products. PCR reactions were done using 
an ABI 7900 Sequence Detection System and 
the thermocycling conditions were 50°C for 
2 minutes followed by 95°C for 2 minutes, 
and then 40 cycles of 95°C for 15 seconds and 
60°C for 30 seconds. Amplication of the target 
transcripts was performed as part of a multiplex 
reaction in which glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as an internal 
control. Asterand’s Global Standard curve was 
used to interpolate transcript copy numbers 
from the quantitative PCR CT values.30Diabetes Ther (2010)  1(2):57-92. 61
RESULTS
All tissues used in this study were obtained 
from ethically approved intermediaries. Tissue 
supply was governed by legal agreements and by 
stringent ethical review from local research ethics 
committees. In addition, and in all cases, the 
informed consent of the donor or the donor’s next 
of kin was obtained for the use of the donated 
tissue for research. In all, 46% of the tissues 
were from female donors while 54% were from 
male donors. The age distributions of the tissue 
donors were: <20 years old: 5%; 20-39 years old: 
17%; 40-60 years old: 32%; 60-80 years old: 31%; 
>80 years old: 14%. No ethnicity information 
relating to tissue donors was available.
The genes that were profiled by quantitative 
RT-PCR for their expression levels across a panel 
of 72  different human tissues are listed by 
both their common name and their systematic 
name in Table 1A. Also listed are the putative 
substrates for each of the transporters, as well as 
the chromosomal location of each transporter 
gene. The primer sequences used for PCR were 
designed to be general for all known isoforms and 
splice variants of each gene. The sequences of the 
amplicons, the exon location of the amplicons, 
and their precise genomic coordinates are listed 
in Table 2.31 Included in each PCR reaction was 
a primer/probe set for the GAPDH gene. This 
was done to control for the success of the first 
strand cDNA synthesis reaction and the eventual 
PCR. These data were not used for normalization 
purposes since GAPDH levels themselves vary 
considerably across the tissue type and individual 
donor.30 The study included total RNA isolated 
from three different individuals for each tissue 
in a panel of 72 tissues. The 72 tissues in the 
study extend across all major human biological 
systems: cardiovascular, digestive, endocrine, 
male and female reproductive, hematopoietic 
and lymphatic, integumentary, musculoskeletal, 
nervous, respiratory, and urinary systems.30 The 
individual RNA samples used in the study were 
prepared from normal tissues, although their 
donors may have had abnormal or diseased 
symptoms in other tissues or organs. The donors 
represent different genders and age groups, 
and every attempt was made to use the same 
samples for the analysis of all seven SGLT family 
members. A few exceptions did occur which bear 
no impact on our study conclusions.
Table 2. Genomic information of the quantitative polymerase chain reaction (PCR) amplicons of sodium glucose 
cotransporter protein (SGLT) family members.
The chromosomal coordinates and exon locations of the amplicons are determined by alignment of the amplicon sequences 
against human genome GRCh37 Assembly (hg19) on the UCSC Genome Browser.3162 Diabetes Ther (2010)  1(2):57-92.
Tissue expression profiling of the seven SGLT 
family members reveals distinct patterns of tissue 
expression, summarized below.
The Kidney-Specific and Kidney-Abundant 
SGLT Family Members
Figure 1A presents the results evaluating 
the expression of SGLT2 from a subset of the 
72 tissues profiled (data from all the tissues are 
available in the Appendix, Additional Figure 
S1) with a primer/probe set (SGLT2-e6,7) 
designed to span the boundaries of exons 6 and 
7 of SGLT2, as noted in Table 2). In all figures 
presented, the Y-axis represents the number 
of transcripts per µg of RNA. The tissue with 
the highest level of expression was the kidney 
cortex where the expression was approximately 
300-fold higher than the tissue with the next 
highest level of expression, the kidney medulla. 
Although small numbers of putative transcripts 
could be observed in some of the other tissues, 
no evidence of SGLT2 expression was observed 
in the majority of other tissues, including the 
20 brain subregion RNA samples tested (eight of 
these are shown in Figure 1A). These data are 
consistent with several other reports evaluating 
the pattern of expression of SGLT2 in human 
tissues.9,10,16 The GAPDH data, plotted in log2
format on the right-hand y-axis of the panel of 
Figure 1A, indicates that all tissue RNA samples 
had successful first strand synthesis and PCR 
reactions. The error bar associated with the 
tissue data indicates the variation observed in 
expression measurements using individual RNA 
samples from three individual donors and not 
that obtained with technical replicates. Our study 
methodology is thus different from other studies 
reported in the literature where pooled samples 
from commercial vendors were utilized.22
Similar data was obtained using three 
additional primer/probe combinations spanning 
different exon regions (exons 1 and 2, exons 4 
and 5, exons 9 and 10) of the SGLT2 gene (see 
the Appendix, Additional Figures S2-S4), further 
supporting that the expression of the SGLT2 gene 
is highly specific for the kidney cortex. Low 
transcript levels were detected across a range of 
tissues outside the kidney for the primer/probe 
set SGLT2-e4,5 (Table S2), possibly due to greater 
primer/probe set efficiency; however, even in this 
case, kidney expression was 100-fold higher than 
in the next highest tissue observed (the ileum). 
In addition, the primer/probe combination 
(SGLT2-e13), located in exon 13 close to the 3’ 
end of the SGLT2 gene and identical to the one 
used by Zhou et al.,22 shows that the SGLT2 gene 
is highly specifically expressed in the kidney 
(Figure 1B, Figure S5, and Table S2), unlike the 
result previously reported by these investigators. 
We observed that this primer/probe set essentially 
mirrors the data obtained with the primer/probe 
set spanning the junction of exons 6 and 7, as 
well as primer/probe sets spanning the exons 1-2, 
4-5, and 9-10. We note that the primer/probe 
SGLT2-e13 lies in a region of overlap with 
another SGLT2-unrelated transcript, and thus 
is less specific to the SGLT2 sequence compared 
with other SGLT2 primer/probes we tested. The 
potential consequences of using this probe are 
further discussed in “the SGLT2 locus” section 
below. In summary, these data suggest that the 
steady state levels of SGLT2 transcripts are highly 
specific for the cortex of the kidney in humans.
SGLT5, a relatively uncharacterized SGLT 
family member, is also found to have a highly 
kidney-abundant tissue expression pattern. 
The expression of SGLT5 in a subset of the 
72 human tissues is shown in Figure 2A (data 
from all 72 human tissues can be found in the 
Appendix, Additional Figure S6). The highest 
expression level of SGLT5 is found in the kidney 
cortex, while in the kidney medulla SGLT5 is 
expressed at about half of the level found in Diabetes Ther (2010)  1(2):57-92. 63
Figure 1. Expression of sodium glucose cotransport protein SGLT2 in human tissues. Copies of SGLT2 transcript per 1 µg 
of total RNA are shown on the left Y-axis of the graph. Log2 value of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
transcript per 1 µg of total RNA is shown on the right Y-axis. A subset of the 72 human tissues is shown on the X-axis. The 
average number of transcripts from tissues of three human donors is shown in each tissue category. The error bar represents 
the standard deviation of transcripts of the three donors. (A) SGLT2 tissue expression from TaqMan quantitative polymerase 
chain reactions (PCR) performed using primer/probe set designed in exon 6-7 of SGLT2 (SGLT2-e6,7); (B) SGLT2 tissue 
expression from TaqMan quantitative PCR reactions performed using primer/probe set designed in exon 13 of SGLT2 
(SGLT2-e13).64 Diabetes Ther (2010)  1(2):57-92.
Figure 2. Expression of sodium glucose cotransport protein SGLT5 in human tissues. Copies of SGLT5 transcript per 1 µg 
of total RNA are shown on the left Y-axis of the graph. Log2 value of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
transcript per 1 µg of total RNA is shown on the right Y-axis. A subset of the 72 human tissues is shown on the X-axis. The 
average number of transcripts from tissues of three human donors are shown in each tissue category. The error bar represents 
the standard deviation of transcripts of the three donors. (A) SGLT5 tissue expression from TaqMan quantitative polymerase 
chain reactions (PCR) performed using primer/probe set designed in exon 11 of SGLT5. (B) Tissue expression of SGLT2 
(primer/probe set in exon 6-7) and SGLT5 (primer/probe set in exon 11) plotted side-by-side in tissues absent of kidney 
cortex or medulla.Diabetes Ther (2010)  1(2):57-92. 65
Figure 3. Expression of sodium glucose cotransport proteins SGLT1, sodium-dependent amino acid transporter (SAAT1), 
and SGLT4 in human tissues. Copies of SGLT1 transcript per 1 µg of total RNA are shown on the left Y-axis of the graph. 
Log2 value of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript per 1 µg of total RNA is shown on the right 
Y-axis. A subset of the 72 human tissues are shown on the X-axis. The average number of transcripts from tissues of three 
human donors is shown in each tissue category. The error bar represents the standard deviation of transcripts of the three 
donors. (A) SGLT1 tissue expression from TaqMan quantitative polymerase chain reations (PCR) performed using primer/
probe set designed in exon 4-5 of SGLT1. (B) Tissue expression of SAAT1 (primer/probe set in exon 2-3) and SGLT4 
(primer/probe set in exon 11) plotted side-by-side.66 Diabetes Ther (2010)  1(2):57-92.
the kidney cortex. Because the extremely high 
level of kidney expression may obscure the 
magnitude of expression observed in other 
tissues, we replotted the data without the kidney 
cortex and medulla data in Figure 2B. Unlike 
the profile observed for SGLT2, which has little 
or no detectable level in tissues other than the 
kidney cortex and medulla, SGLT5 exhibits a 
low level of expression in some tissues like the 
kidney pelvis, vas deferens, left atrium of the 
heart, skin, and testes. However, the expression 
of SGLT5 in the kidney cortex is still 35 times 
higher than that observed in the vas deferens. 
These data suggest that the expression of SGLT5 
in human tissues is highly abundant in kidney, 
compared with other tissues.
The Small Intestine and Muscle-Abundant 
SGLT Family Members
As shown in Figure 3A, the expression of 
SGLT1 (SLC5A1), the closest homolog to SGLT2, 
is essentially restricted to the small intestine, 
the skeletal muscle, and the heart (the data 
for all 72 human tissues are in the Appendix, 
Additional Figure S7 and Additional Table S2). 
Minor numbers of transcripts are observed in the 
trachea, prostate, cervix, and mesenteric adipose 
tissue, but like SGLT2, we see no evidence for 
any expression in the brain subregions tested. 
The GAPDH data indicates successful first 
strand synthesis and PCR in all samples. The 
expression pattern of SGLT1 across human 
tissues we observed above is generally consistent 
with reports from other studies using mRNA-
based methods.6,7,9 It is worth noting that brain 
expression of SGLT1 has been reported in other 
species (rats and pigs) using immunological, in 
situ hybridization and RT-PCR techniques.29,32,33
Interestingly, the glucose sensor SAAT1 
(SLC5A4) and the low-affinity glucose/mannose 
cotransporter SGLT4 (SLC5A9) display a similar 
high level of expression in the small intestine 
(duodenum, jejunum, and ileum) as well as in 
skeletal muscle (Figure 3B; data for all 72 human 
tissues are in the Appendix, Additional 
Figures S8 and S9). In the case of SAAT1, the 
highest expression could be found in the 
jejunum, and the steady state SAAT1 RNA level 
there is about 3.5-fold higher than in skeletal 
muscle. These data are consistent with other 
reports of SAAT1 expression in the intestine and 
skeletal muscle.11,13 The steady state SGLT4 RNA 
level in the ileum is on the order of 5-fold higher 
than the next highest-expressing tissue outside 
of the gastrointestinal (GI) tract, the skeletal 
muscle. The expression of SGLT1, SAAT1, and 
SGLT4 in the GI tract seems to be enriched 
in the small intestinal region: duodenum, 
jejunum, and ileum; whereas these genes are 
expressed at a much lower level in the large 
intestine (cecum, colon, and rectum) as well as 
in other parts of the GI tract such as stomach 
and oesophagus (Figure 3). Unlike SGLT1, 
SAAT1 and SGLT4 display a much lower level 
of expression in the heart. On the other hand, 
SGLT4 has a uniquely moderate expression level 
in pancreas compared with SGLT1 and SAAT1. 
In all other tissues tested, SGLT1, SAAT1, and 
SGLT4 have a generally low level of expression 
(see the Appendix, Additional Figures S7, S8, 
and S9). Overall, the profile observed here 
for SGLT4 expression across human tissues is 
similar to that previously reported.16
The Brain Expresses SGLT6
The solute carrier family 5A11 or SGLT6, 
a cotransporter with substrate specificity 
for myo-inositol and glucose, seems to be 
the only SGLT family member, aside from 
the ubiquitously-expressed SMIT (see next 
section), that has extensive expression in all 
the brain subregions tested. We observed high Diabetes Ther (2010)  1(2):57-92. 67
steady state RNA levels of SGLT6 collectively 
in the brain, with the highest subregion being 
the substantia nigra where it was found to 
be expressed at levels 2-5-fold higher than 
the other regions tested (Figure 4; data for 
all 72 human tissues are in the Appendix, 
Additional Figure S10). SGLT6 is also highly 
expressed in the spinal cord, at a level similar 
to that in substantia nigra. However, it is not 
detected in the dorsal root ganglion (DRG). 
Other tissue RNA samples with notable 
expression levels of SGLT6 are the small 
intestine (ileum and jejunum), kidney (cortex 
and medulla), as well as skeletal muscle. The 
observed pattern of SGLT6 in these studies 
appears to be unique among the SGLT family 
members tested, and if this pattern is similar 
in rodents, SGLT6 activity could account, at 
least in part, for the observation of functional 
SGLT expression in rat brain.29 It is interesting 
to note that the human genomic location of 
SGLT6 coincides with a locus associated with 
the nervous system disorders of infantile 
convulsions and choreoathetosis, though no 
disease-associated mutations were found in 
the exon or intron/exon boundary sequences 
of the SGLT6 gene.18 The pattern of expression 
in human tissues described here differs from 
that initially described by northern blot,18
although brain expression was detected in 
both studies.
The Ubiquitously Expressed SMIT
The sodium myo-inositol cotransporter 
SMIT (SLC5A3) shows a ubiquitous pattern of 
expression with the highest expression level 
in the medulla of the kidney and the blood 
vessel of the choroid plexus (Figure 5; data 
for all 72 human tissues are in the Appendix, 
Figure 4. Expression of sodium glucose cotransport protein SGLT6 in human tissues. Copies of SGLT6 transcript per 1 µg 
of total RNA are shown on the left Y-axis of the graph. Log2 value of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
transcript per 1 µg of total RNA is shown on the right Y-axis. A subset of the 72 human tissues are shown on the X-axis. The 
average number of transcripts from tissues of three human donors is shown in each tissue category. The error bar represents 
the standard deviation of transcripts of the three donors.68 Diabetes Ther (2010)  1(2):57-92.
Additional Figure S11). The thyroid gland, pineal 
gland, dorsal root ganglion, and the testes also 
have high levels of SMIT expression. Overall, the 
pattern of expression of SMIT is consistent with 
what has been previously reported,14 and its 
expression in all tissues examined highlights its 
potentially important role in the maintenance 
of osmotic balance within cells.
The SGLT2 Locus
The discrepancy between our results and that 
reported by Zhou et al.22 prompted us to examine 
the SGLT2 locus in more detail. The SGLT2 gene 
resides on chromosome 16 where 14 exons span 
approximately 7 kilobases of genomic DNA. The 
last two exons, exon 13 and 14, overlap with 
exon 13 of a gene that is encoded on the opposite 
strand, called C16orf58 (Figure 6A). This gene, 
conserved in plants, invertebrates, and vertebrates, 
contains 13 exons spanning 20 kb of genomic 
DNA, and encodes a protein homologous to the 
Arabidopsis RUS1 gene.34,35 Numerous sequence 
submissions to Genbank suggest C16orf58 is 
indeed expressed. Our internal cDNA cloning 
effort has obtained full-length cDNA clone of 
C16orf58. The C16orf58 cDNA clone has a long 
3’ untranslated region that contains the reverse-
complement sequence of exon 13 and 14 of the 
SGLT2 gene (data not shown). Electronic northern 
blots using the region of overlap as a ‘probe’ 
indicates that expressed sequence tags (ESTs) 
for C16orf58 versus that of SGLT2 can be found 
in the NBCI database at the relative abundance 
of 10 transcripts to one (data not shown). We 
designed a primer/probe set located in exon 8 of 
C16orf58 and one that is specific for C16orf58 
(Figure 6B). Expression profiling analysis with 
this primer/probe set indicates that this gene is 
expressed ubiquitously with the highest steady 
state RNA levels also located in the cortex of 
the kidney, the cerebellum (Figure 6C), and the 
Figure 5. Expression of sodium myo-inositol cotransporter (SMIT) in human tissues. Copies of SMIT transcript per 1 µg of 
total RNA are shown on the left Y-axis of the graph. Log2 value of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
transcript per 1 µg of total RNA is shown on the right Y-axis. A subset of the 72 human tissues are shown on the X-axis. The 
average number of transcripts from tissues of three human donors is shown in each tissue category. The error bar represents 
the standard deviation of transcripts of the three donors.Diabetes Ther (2010)  1(2):57-92. 69
Figure 6. Analysis of the sodium glucose cotransport protein SGLT2 locus in human genome. (A) A genome browser view 
of the 22 kb region of the human SGLT2 locus in chromosome 16 obtained from the UCSC Genome Browser of the human 
genome GRCh37 Assembly (hg19). The red rectangular box highlights the overlapping of exon 13 and 14 of SGLT2 with 
exon 13 of C16orf58. (B) Schematic drawing of the exon structure of the SGLT2 gene and C16orf58 gene on chromosome 
16. Green block arrows represent the open reading frames of the genes. Pink block arrows represent the exons of SGLT2 gene 
while yellow block arrows represent the exons of C16orf58 genes. Locations of amplicons of TaqMan quantitative 
polymerase chain reactions (PCR) are represented by red arrow heads. (C) Copies of C16orf58 transcript per 1 µg of 
total RNA are shown on the left Y-axis of the graph. Log2 value of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
transcript per 1 µg of total RNA is shown on the right Y-axis. A subset of the 72 human tissues are shown on the X-axis. The 
average number of transcripts from tissues of three human donors is shown in each tissue category. The error bar represents 
the standard deviation of transcripts of the three donors.70 Diabetes Ther (2010)  1(2):57-92.
thyroid (see the Appendix, Additional Figure S12). 
The primer/probe set (SGLT2-e13) used by Zhou 
et al.22 resides in exon 13 of SGLT2, in the area of 
overlap between SGLT2 and C16orf58 (Figure 6B), 
suggesting that measurement of both transcripts 
would be confounding in experiments where 
poly d(T) was used to prime first strand synthesis 
in a one-step PCR process. We have used each of 
the primers employed by these investigators in 
separate first strand reactions and have shown 
that the reverse primer is capable of synthesizing 
kidney cortex abundant SGLT2 cDNA (Figure 1B), 
however we have been unable to recapitulate 
the expression pattern seen with the C16orf58-
specific primer (Figure 6C) using the Zhou et al.22
forward primer (data not shown).
DISCUSSION
We have used quantitative RT-PCR to 
examine the expression profile of SGLT2 and 
related family members across a panel of 
72 tissues from three healthy individuals. This 
study is the most comprehensive analysis done 
to date on this important family of sodium-
monosaccharide cotransporters, and was carried 
out to increase our understanding of where these 
transporters are expressed in human tissues. 
The data presented clearly demonstrates that 
SGLT2 is expressed primarily in the cortex of 
the kidney at steady state levels that are several 
hundred-fold greater than the tissue with the 
next highest abundance, the kidney medulla. 
We have confirmed these data with multiple 
primer/probe combinations representing 
essentially the entire SGLT2 locus.
These data are in agreement with some 
previous studies9,16,20 but in conflict with 
others,21,22 who reported that SGLT2 showed 
a more widespread pattern of expression. We 
have attempted to reconcile our results with 
those of Zhou et al.22 by using their primer/
probe combination in conjunction with our 
PCR methodology, which uses orientation-
specific first strand cDNA synthesis; however, we 
were unable to reproduce their results. Instead 
we demonstrate that like that obtained with 
all SGLT2 primer/probe combinations tested, 
SGLT2 is indeed restricted in its expression 
to the cortex of the kidney. We analyzed the 
SGLT2 locus and discovered that the primer/
probe amplicon SGLT2-e13 overlaps with 
extreme 3’ end of another gene encoded on the 
opposite strand, C16orf58. Our results indicate 
that this conserved gene with homology to the 
Arabidopsis RUS1 gene34,35 is indeed ubiquitously 
expressed at moderately abundant levels in 
all 72 tissues tested and is also expressed in 
the cortex of the kidney. We attempted to use 
the forward primer employed by Zhou et al.22
to prime first strand synthesis of the 3’ end of 
C16orf58 followed by PCR, to determine if that 
method could give rise to the expression profile 
they reported, but we were unable to recapitulate 
the published profile, nor could we replicate 
the profile obtained with the C16orf58-specific 
primer/probe set located in exon 8. Either the 
C16orf58 forward primer is inefficient in this role 
as a primer of first strand synthesis, or the 3’ end 
of the C16orf58 transcript is particularly unstable 
and easily degraded. However, the large number 
of Express Sequence Tags that can be found in 
Genbank generated from the C16orf58 strand 
that overlaps the 3’ end of SGLT2 as well as our 
own internal C16orf58 cloning efforts suggests 
that the latter is not the case.
To better understand the physiological 
consequences of agonizing and antagonizing 
protein function it is extremely important 
to know in which tissues a gene is expressed, 
particularly from the viewpoint of assessing 
potential liabilities. Included in the tissue 
panel was RNA isolated from 20 different brain 
subregions. We see no evidence that SGLT2 is Diabetes Ther (2010)  1(2):57-92. 71
expressed in any of the brain subregions tested, 
even though the same RNA samples were used for 
other profiles that did return detectable transcript 
numbers, e.g. SGLT6, where 52 out of 60 brain 
subregion RNA samples used in both experiments 
were identical, and the GAPDH control indicated 
successful enzymatic reactions. However, this 
conclusion is limited by the detection level 
afforded by quantitative PCR methodologies, and 
we can not rule out the possibility that SGLT2 is 
expressed within small numbers of discrete brain 
cells, as well as other tissues, that are undetectable 
by the TaqMan protocol.
Another method to evaluate RNA expression 
is by Affymetrix RNA chip hybridization. The 
human SGLT2 gene is represented by probe 
set 207771_at on Affymetrix RNA chips. The 
mouse SGLT2 gene is represented by probe 
sets 1419166_at and 1455005_a_at, while rat 
SGLT2 is represented by probe set U29881_at. 
The public domain gene expression database 
BioGPS36 contains tissue expression profiling 
data for these probe sets (see the Appendix, 
Additional Figure S13). In the Affymetrix chip 
database, SGLT2 transcripts are found to be 
highly specific to the kidney tissue of human, 
mouse, and rat, consistent with our human 
tissue quantitative RT-PCR study results. 
These data are further supported by the recent 
publication of immunohistochemical data in 
mice, confirming the original localization of 
the rodent SGLT2 protein to the early proximal 
tubule,19 which was clearly absent in the SGLT2 
knock-out mouse.27
Certainly, the sodium/glucose cotransporter 
family member with the closest expression profile 
to that of SGLT2 is SGLT5, which is expressed 
almost exclusively in the cortex and medulla of 
the kidney. The only other tissues that show a 
much lower level of expression are the heart, 
skin, and vas deferens. This highly restricted gene 
expression suggests a kidney-specific function, 
however, little is known about this gene and 
its gene product, including what its substrate 
specificity may be. Hence the putative role of 
this protein in regulating solute homeostasis in 
the kidney remains to be determined.
The SGLT1 expression profile agrees with the 
well-established role of this gene as encoding 
the intestinal high-affinity low capacity glucose 
reabsorption cotransporter6 with the highest 
steady state levels being observed in the ileum 
and other regions of the small intestine.7 The 
observed expression of SGLT1 in the ventricle of 
the heart agrees with that reported by Zhou et 
al.22 as well as with our own unpublished data 
(Hagan D., data not shown). It is curious to note 
that SGLT1 expression in the heart is apparently 
restricted to humans, since no expression of 
SGLT1 is detectable in the heart tissue of rats,7
dogs, pigs, or cynomolgus monkeys (Hagan D., 
unpublished results.) Our data also suggest that 
transcripts for SGLT1 can be found in skeletal 
muscle at a level similar to the heart. The 
relative high level of SGLT1 expression in heart 
and skeletal muscle suggests that it might play a 
significant but yet-to-be-defined role in glucose 
absorption in those tissues.
The glucose transporters SAAT1 and SGLT4, 
the latter also having affinity for mannose as 
a substrate, have a surprisingly similar tissue 
expression pattern in the small intestine 
and skeletal muscle compared to SGLT1. 
Interestingly, the expression of these three 
SGLT member genes seem to be limited to the 
small intestinal portion of the GI tract with 
the duodenum, jejunum, and ileum all having 
the most prominent levels of detectable RNA; 
other parts of the GI tract, such as the cecum, 
colon, rectum, and the stomach have much 
lower level of gene expression. However, unlike 
SGLT1, SAAT1 and SGLT4 do not have a high 
level of expression in the heart. SGLT4 also 
demonstrates high level of expression in the 72 Diabetes Ther (2010)  1(2):57-92.
pancreas, although at this time we do not know 
which specific cell types in the pancreas may 
contribute to the overall steady state level of 
RNA. The specific overlap in tissue expression 
pattern of SGLT1, SAAT1, and SGLT4 suggest that 
these three SGLT members could have similar 
and/or complementary functions in the body. 
Based on the localization of the SAAT1 protein, 
and the observation of ion transport decoupled 
from glucose transport activity, Diez-Sampedro 
and colleagues have proposed a role for SAAT1 
as a glucose sensor in cholinergic neurons of 
the GI tract and at neuromuscular junctions, 
as a potential modulator of gastric motility and 
muscular activity.13
We show here that SGLT6, a gene recently 
implicated in a genetic association study to be a 
modifying locus of systemic lupus erythematosis 
(SLE), displays a neuronal expression pattern 
suggesting an additional putative role for this 
gene outside that of the immune system in 
regulating myo-inositol homeostasis in the brain 
and spinal cord.37 Interestingly, our data does not 
support an immune cell expression pattern but 
instead indicates that SGLT6 is not significantly 
expressed (at the level of quantitative RT-PCR 
resolution) outside of the nervous system, the 
small intestine, and the kidney.
Given the interest in SGLT2 inhibitors as a 
potential therapeutic approach for diabetes, 
it is worth noting that not only is the tissue 
localization of SGLT2 expression relevant to the 
therapeutic profile, but also the selectivity profile 
for inhibitors currently in clinical development, 
since a lack of specificity for one or more 
other SGLT proteins could have physiological 
consequences beyond the kidney. Various 
groups have reported the in vitro, assay-specific 
50% inhibitory concentration (IC50)-based 
selectivity of SGLT2 inhibitors versus SGLT1, 
with dapagliflozin and BI 10773 showing the 
highest degree of selectivity: 1241-fold and 
>2500-fold selectivity, respectively;38,39 whereas 
the compounds canagliflozin, ASP1941, and 
LX4211 have reported selectivities of 414-, 255- 
and 20-fold, respectively.40,41,42 The activity of 
these compounds vs. other members of the SGLT 
family have not been consistently reported to 
date. Once the inhibitory constant (Ki) values, 
generated from data obtained across a range 
of substrate concentrations, are reported, the 
values should be more directly comparable 
across compounds. The impact of the overall 
selectivity profile of these agents should become 
clear as the therapeutic profile emerges during 
clinical development.
CONCLUSION
In summary, in order to better understand 
the spectrum of human tissues in which 
the sodium-glucose cotransporter family of 
proteins is expressed, we have examined the 
mRNA expression profile of human SGLT2 
and six of its homologs (SGLT1, SAAT1, 
SMIT, SGLT4, SGLT5, SGLT6) in a panel of 
72 normal human tissues from three separate 
donors using quantitative RT-PCR methods. 
For SGLT2, using five different primer/probe 
sets spanning the entire locus, we confirm the 
kidney-specific expression of this gene. Thus 
we conclude that SGLT2 expression is highly 
restricted to the kidney in humans, and that 
the expression of related proteins of this family, 
with the exception of SGLT5, diverges from 
this kidney specificity. It is a highly desirable 
requirement that the expression of a protein 
drug target be restricted to the tissue where 
its therapeutic effects can be most efficacious. 
The work presented here demonstrating the 
kidney-specific expression of SGLT2 helps to 
satisfy this requirement and further augments 
the importance and value of this protein as a 
drug target for treatment of diabetes.Diabetes Ther (2010)  1(2):57-92. 73
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APPENDIX
Additional Table S1. Primer/probe sequences of TaqMan quantitative polymerase chain reactions (PCR).
The forward, reverse primer sequences and the TaqMan Probe sequence of the PCR reactions are given in the table. Sodium 
glucose cotransporter protein SGLT2-e1,2: amplicon spans exon 1 and 2 of the SGLT2 gene; SGLT2-e4,5: amplicon spans 
exon 4 and 5 of the SGLT2 gene; SGLT2-e6,7: amplicon spans exon 6 and 7 of the SGLT2 gene; SGLT2-e9,10: amplicon 
spans exon 9 and 10 of the SGLT2 gene; SGLT2-e13: amplicon is located in exon 13 of the SGLT2 gene; SAAT=sodium-
dependent amino acid transporter; SMIT=sodium myo-inositol cotransporter.
SAAT=sodium-dependent amino acid transporter; SMIT=sodium myo-inositol cotransporter.Diabetes Ther (2010)  1(2):57-92. 77
Additional Table S2. Expression of sodium glucose cotransporter proteins SGLT1 and SGLT2 in selected human tissues.
The numbers of SGLT1 and SGLT2 molecules per µg of RNA in selected human tissues are shown in the table. SGLT2-e1,2: 
amplicon spans exon 1 and 2 of the SGLT2 gene; SGLT2-e4,5: amplicon spans exon 4 and 5 of the SGLT2 gene; SGLT2-
e6,7: amplicon spans exon 6 and 7 of the SGLT2 gene; SGLT2-e9,10: amplicon spans exon 9 and 10 of the SGLT2 gene; 
SGLT2-e13: amplicon is located in exon 13 of the SGLT2 gene.78 Diabetes Ther (2010)  1(2):57-92.
Additional Figure S1. Expression of sodium 
glucose cotransporter protein SGLT2 in 
human tissues measured by primer/probe set 
on exons 6-7. Copies of SGLT2 transcript 
per 1 µg of total RNA are shown on the 
top X-axis of the graph. Log2 value of 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) transcript per 1 µg of total 
RNA is shown on the bottom X-axis. All 
72 human tissues are shown on the Y-axis. 
The average number of transcripts from 
tissues of three human donors is shown in 
each tissue category. The error bar represents 
the standard deviation of transcripts of the 
three donors. SGLT2 tissue expression from 
TaqMan quantitative polymerase chain 
reactions (PCR) performed using primer/
probe set designed in exon 6-7 of SGLT2 
(SGLT2-e6,7).Diabetes Ther (2010)  1(2):57-92. 79
Additional Figure S2. Expression of sodium 
glucose cotransporter protein SGLT2 in 
human tissues measured by primer/probe set 
on exons 1-2. Copies of SGLT2 transcript 
per 1 µg of total RNA are shown on the 
top X-axis of the graph. Log2 value of 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) transcript per 1 µg of total 
RNA is shown on the bottom X-axis. All 
72 human tissues are shown on the Y-axis. 
The average number of transcripts from 
tissues of three human donors is shown in 
each tissue category. The error bar represents 
the standard deviation of transcripts of the 
three donors. SGLT2 tissue expression from 
TaqMan quantitative polymerase chain 
reactions (PCR) performed using primer/
probe set designed in exon 1-2 of SGLT2 
(SGLT2-e1,2).80 Diabetes Ther (2010)  1(2):57-92.
Additional Figure S3. Expression of sodium 
glucose cotransporter protein SGLT2 in 
human tissues measured by primer/probe set 
on exons 4-5. Copies of SGLT2 transcript 
per 1 µg of total RNA are shown on the 
top X-axis of the graph. Log2 value of 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) transcript per 1 µg of total 
RNA is shown on the bottom X-axis. All 
72 human tissues are shown on the Y-axis. 
The average number of transcripts from 
tissues of three human donors is shown in 
each tissue category. The error bar represents 
the standard deviation of transcripts of the 
three donors. SGLT2 tissue expression from 
TaqMan quantitative polymerase chain 
reactions (PCR) performed using primer/
probe set designed in exon 4-5 of SGLT2 
(SGLT2-e4,5).Diabetes Ther (2010)  1(2):57-92. 81
Additional Figure S4. Expression of sodium 
glucose cotransporter protein SGLT2 in 
human tissues measured by primer/probe set 
on exons 9-10. Copies of SGLT2 transcript 
per 1 µg of total RNA are shown on the 
top X-axis of the graph. Log2 value of 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) transcript per 1 µg of total 
RNA is shown on the bottom X-axis. All 
72 human tissues are shown on the Y-axis. 
The average number of transcripts from 
tissues of three human donors is shown in 
each tissue category. The error bar represents 
the standard deviation of transcripts of the 
three donors. SGLT2 tissue expression from 
TaqMan quantitative polymerase chain 
reactions (PCR) performed using primer/
probe set designed in exon 9-10 of SGLT2 
(SGLT2-e9,10).82 Diabetes Ther (2010)  1(2):57-92.
Additional Figure S5. Expression of sodium 
glucose cotransporter protein SGLT2 in 
human tissues measured by primer/probe 
set on exons 13. Copies of SGLT2 transcript 
per 1 µg of total RNA are shown on the 
top X-axis of the graph. Log2 value of 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) transcript per 1 µg of total 
RNA is shown on the bottom X-axis. All 
72 human tissues are shown on the Y-axis. 
The average number of transcripts from 
tissues of three human donors is shown in 
each tissue category. The error bar represents 
the standard deviation of transcripts of the 
three donors. SGLT2 tissue expression from 
TaqMan quantitative polymerase chain 
reactions (PCR) performed using primer/
probe set designed in exon 13 of SGLT2 
(SGLT2-e13).Diabetes Ther (2010)  1(2):57-92. 83
Additional Figure S6. Expression of sodium 
glucose cotransporter protein SGLT5 in 
human tissues. Copies of SGLT5 transcript 
per 1 µg of total RNA are shown on the 
top X-axis of the graph. Log2 value of 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) transcript per 1 µg of total 
RNA is shown on the bottom X-axis. All 
72 human tissues are shown on the Y-axis. 
The average number of transcripts from 
tissues of three human donors is shown in 
each tissue category. The error bar represents 
the standard deviation of transcripts of the 
three donors.84 Diabetes Ther (2010)  1(2):57-92.
Additional Figure S7. Expression of sodium 
glucose cotransporter protein SGLT1 in 
human tissues. Copies of SGLT transcript 
per 1 µg of total RNA are shown on the 
top X-axis of the graph. Log2 value of 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) transcript per 1 µg of total 
RNA is shown on the bottom X-axis. All 
72 human tissues are shown on the Y-axis. 
The average number of transcripts from 
tissues of three human donors is shown in 
each tissue category. The error bar represents 
the standard deviation of transcripts of the 
three donors. SGLT1 tissue expression from 
TaqMan quantitative polymerase chain 
reactions (PCR) performed using primer/
probe set designed in exon 4-5 of SGLT1.Diabetes Ther (2010)  1(2):57-92. 85
Additional Figure S8. Expression of sodium-
dependent amino acid transporter (SAAT1) 
in human tissues. Copies of sodium glucose 
cotransporter protein (SGLT) transcript 
per 1 µg of total RNA are shown on the 
top X-axis of the graph. Log2 value of 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) transcript per 1 µg of total 
RNA is shown on the bottom X-axis. All 
72 human tissues are shown on the Y-axis. 
The average number of transcripts from 
tissues of three human donors is shown in 
each tissue category. The error bar represents 
the standard deviation of transcripts of the 
three donors. SAAT1 tissue expression from 
TaqMan quantitative polymerase chain 
reactions (PCR) performed using primer/
probe set designed in exon 2-3 of SAAT1.86 Diabetes Ther (2010)  1(2):57-92.
Additional Figure S9. Expression of sodium 
glucose cotransporter (SGLT4) in human 
tissues. Copies of SGLT transcript per 1 µg 
of total RNA are shown on the top X-axis 
of the graph. Log2 value of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) 
transcript per 1 µg of total RNA is shown 
on the bottom X-axis. All 72 human tissues 
are shown on the Y-axis. The average number 
of transcripts from tissues of three human 
donors is shown in each tissue category. The 
error bar represents the standard deviation of 
transcripts of the three donors. SGLT4 tissue 
expression from TaqMan quantitative 
polymerase chain reactions (PCR) 
performed using primer/probe set designed 
in exon 11 of SGLT4.Diabetes Ther (2010)  1(2):57-92. 87
Additional Figure S10. Expression of 
sodium glucose cotransporter protein 
SGLT6 in human tissues. Copies of 
SGLT6 transcript per 1 µg of total RNA 
are shown on the top X-axis of the graph. 
Log2 value of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) transcript per 
1 µg of total RNA is shown on the bottom 
X-axis. All 72 human tissues are shown on 
the Y-axis. The average number of transcripts 
from tissues of three human donors is 
shown in each tissue category. The error 
bar represents the standard deviation of 
transcripts of the three donors.88 Diabetes Ther (2010)  1(2):57-92.
Additional Figure S11. Expression of 
sodium myo-inositol cotransporter (SMIT) 
in human tissues. Copies of SMIT transcript 
per 1 µg of total RNA are shown on the 
top X-axis of the graph. Log2 value of 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) transcript per 1 µg of total 
RNA is shown on the bottom X-axis. All 
72 human tissues are shown on the Y-axis. 
The average number of transcripts from 
tissues of three human donors is shown in 
each tissue category. The error bar represents 
the standard deviation of transcripts of the 
three donors.Diabetes Ther (2010)  1(2):57-92. 89
Additional Figure S12. Expression of 
C16orf58 in human tissues. Copies of 
C16orf58 transcript per 1 µg of total RNA 
are shown on the top X-axis of the graph. 
Log2 value of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) transcript per 
1 µg of total RNA is shown on the bottom 
X-axis. All 72 human tissues are shown on 
the Y-axis. The average number of transcripts 
from tissues of three human donors is 
shown in each tissue category. The error 
bar represents the standard deviation of 
transcripts of the three donors.90 Diabetes Ther (2010)  1(2):57-92.
Additional Figure S13. Expression of SGLT2 in 
human, mouse and rat tissues by Affymetrix RNA chip 
hybridization. SGLT2 gene is represented by probeset 
207771_at (http://biogps.gnf.org/?referer=symatlas
#goto=genereport&id=6524) in Affymetrix human 
chips, 1419166_at and 1455005_s_at (http://biogps.
gnf.org/#goto=genereport&id=246787) in Affymetrix 
mouse chips and U29881_at (http://biogps.gnf.
org/#goto=genereport&id=64522) in Affymetrix 
rat chips.Diabetes Ther (2010)  1(2):57-92. 9192 Diabetes Ther (2010)  1(2):57-92.